home technology applications about us news
Our approach is quite different from conventional CE. Through gathering data from many  hundreds of points and using proprietary signal processing algorithms, our technology is able  to produce better quality results than competing CE systems.  deltaDOT patented multipoint  detection system (512 detection points, each sampling at around 20 cycles per second) tracks  the passage of biomolecule bands across the detection window. The proprietary software  derived from particle physics can determine which of the signals relate to the sample and  which do not, thus eliminating any extraneous effects and inaccuracies. deltaDOT's advanced  signal processing technology combined with multi-point detection produces high quality data,  i.e. sensitivity, resolution, quantification and repeatability.
deltaDOT HPCE instruments 
Conventional  Capillary  Electrophoresis  systems use single point detection. This  means each band of biomolecules is measured by just one detector.  As a result biomolecules often need to be 'labelled' with radiochemical, fluorescent, calorimetric, or luminescent compounds. Such CE instruments cannot differentiate between  extraneous interference, electrical noise, light source fluctuations and other undesirable effects.
Conventional CE 
Vertexing demo 
The core science behind LFII® originated in particle physics and is now being applied by  deltaDOT to biochemical analysis using Capillary Electrophoresis. The key to LFII® is the use  of a multi-pixel photo diode array (PDA) and the processing of the acquired signals. This  large  data set is analysed by acquiring data from each band of biomolecules as it traverses each  pixel at a specific time point allowing for a distance-time correlation to be achieved. The  system measures the time it takes for any one band of biomolecules to traverse the detector  array and the software enables the molecular weight or charge-to-mass ratio to be calculated  from its velocity. This greatly improves signal-to-noise ratio offering molecular imaging which  outperforms single point detection systems. The deltaDOT system only works with the signals  that intersect the Vertex enabling LFII® to discriminate between system background noise -  the technique known as Vertexing.
Introduction to the HPCE-512 
HPCE-512 technology selling into the biomedical, biopharmaceutical and analytics markets.  The company has sold nearly 30 systems so far. At its core is the proprietary Label Free  Intrinsic Imaging (LFII®) approach. LFII® has significant advantages over other approaches. It  has a wide spread of applications and customers in many sectors including biotech, academic,  industrial and government sectors. This technology addresses the PAGE, HPLC and to some  extent the Mass Spec markets.
18 January 2018 deltaDOT Ltd. announce successful licensing of their High Performance  Capillary Electrophoresis technology (HPCE) to a leading Chinese company. Last month  deltaDOT entered into a collaboration agreement with a Chinese partner to purchase all  deltaDOT’s technical know-how, software and IP licenses for their High Performance Capillary  Electrophoresis (HPCE) technology (...more)  18 December 2017 The subject of the new Technology partnership publication by deltaDOT is  Glatiramer Acetate Analysis as applied in immunomodulator treatment for multiple sclerosis. On demand analytics of high quality and cost effective nature are described in this application note  (...more)  13 October 2017 deltaDOT continues with Technology partnership publication (www.ttp.com)  The TTP Journal of Technology and Business Innovation provides technical insight into UK  advanced scientific businesses. New articles are now available on Water Ionic Analysis (...more)  and Nicotine Analysis (...more).  8 September 2017 deltaDOT are launching a new series of articles dD Techniques on the  capabilities of their High Performance Label Free Imaging Capillary Electrophoresis technology.  The articles offer accessible information and an insight into this unique technology which is used  worldwide to solve challenging analytical problems. A new perspective on the tools required for  the development and manufacture of monoclonal antibodies, biosimilars, stratified therapies,  viral vaccines and gene therapy vectors highlights the need for new analytical techniques.  These new perspectives are the aims which dD Techniques articles intend to deliver to a wide  range of audience (...links to article1, article2, article3)  24 August 2017 The Technology partnership publication (www.ttp.com) now includes key facts  and data on deltaDOT’s High Precision Capillary Electrophoresis advanced technology. The TTP  Journal of Technology and Business Innovation provides technical insight into UK advanced  scientific businesses (...more) 3rd July 2017 Future Targeted Healthcare Manufacturing. deltaDOT announce their  participation in the new EPSRC funded Future Targeted Healthcare Manufacturing Hub, led by  UCL (...more). The Hub will address the manufacturing, business and regulatory challenges to  ensure that new targeted biological medicines can be developed quickly and manufactured at  affordable costs (...more).   24th January 2017 – deltaDOT Ltd. announces compliance with CFR 21 part 11 of USA’s Food  and Drug Administration. deltaDOT now offers an upgraded version of its control and analysis  software which has been designed to aid users of deltaDOT’s HPCE-512 Hig Performance  Capillary Electrophoresis instrument in achieving compliance with CFR 21 part 11.The upgrade  package contains controls to help meet the stringent requirements of CFR 21 part 11 including  the system access by authorised personel only, maintaining audit trails of user actions,  generating complete and protected data files and the application of electronic signatures to data  (...more)  20 Sep 2016 National Health Service Quality Control North West (QCNW) Liverpool  labs  presented the data on monoclonal antibody stability trials based on deltaDOT’s Capillary  Electrophoresis (CE) technology  and expertise. They state that CE technology is suitable for  monitoring the stability of monoclonal antibodies and can perform purity and charge analysis with  high resolution and repeatability. They conclude that CE can replace other techniques commonly  used for this analysis IEC and SDS PAGE (link to the poster).  3rd July 2016 Monoclonal Antibody Stability Trials using deltaDOT HPCE-512 technology  reported by Dr. Deepika Devanur. Now available in pdf slide format on our website (...more) 
Monoclonal Antibody 
Monoclonal Antibody Stability Trials Using High Performance Capillary Electrophoresis. Dr.  Deepika Devanur’s presentation at the Proteins and Antibodies Congress 18tgh - 19th April  2016. This presentation demonstrates the use of the HPCE-512 Capillary Electrophoresis  platform to provide a complete characterisation of a mAb product using a single analytical tool.  The use of HPCE to characterise the mAbs Rituximab and Infliximab 
HPCE LFII instrument 
Reliability and automation of  deltaDOT Analytical instruments is suitable for unattended (e.g.  overnight) operation which can increase productivity. deltaDOT Label Free LFII® system’s  superior performance and sensitivity obviate the need for expensive (and often toxic) chemical  labels. Design ergonomics, user friendly interface and unsurpassed results in one compact  bench top instrument often resulting in reducing the laboratory costs and overheads. 
Stability Trials